HIV-Host Interactions: Implications for Vaccine Design

Cell Host and Microbe

Volumn 19, Issue 3, 2016, Pages 292-303

  Haynes, Barton F ^a   Shaw, George M ^b   Korber, Bette ^c   Kelsoe, Garnett ^a   Sodroski, Joseph ^d   Hahn, Beatrice H ^b   Borrow, Persephone ^e   McMichael, Andrew J ^e  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c LOS ALAMOS NATIONAL LABORATORY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

CD8+ T LYMPHOCYTE; DRUG DESIGN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS CELL INTERACTION; VIRUS TRANSMISSION; ANIMAL; DRUG DEVELOPMENT; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; PATHOGENICITY; PRECLINICAL STUDY; PRIMATE; PROCEDURES; TREATMENT OUTCOME; TRENDS;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; CD8-POSITIVE T-LYMPHOCYTES; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HIV ANTIBODIES; HIV-1; HOST-PATHOGEN INTERACTIONS; PRIMATES; TREATMENT OUTCOME;

EID: 84959094671     PISSN: 19313128     EISSN: 19346069     Source Type: Journal    
DOI: 10.1016/j.chom.2016.02.002     Document Type: Review

References (115)

1. S. Abdul-Jawad, B. Ondondo, A. van Hateren, A. Gardner, T. Elliott, B. Korber, and T. Hanke Increased valency of conserved-mosaic vaccines enhances the breadth and depth of epitope recognition Mol. Ther. 2016 10.1038/mt.2015.210
2. S.M. Alam, S.M. Dennison, B. Aussedat, Y. Vohra, P.K. Park, A. Fernández-Tejada, S. Stewart, F.H. Jaeger, K. Anasti, J.H. Blinn, and et al. Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors Proc. Natl. Acad. Sci. USA 110 2013 18214 18219
3. R. Andrabi, J.E. Voss, C.H. Liang, B. Briney, L.E. McCoy, C.Y. Wu, C.H. Wong, P. Poignard, and D.R. Burton Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design Immunity 43 2015 959 973
4. P. Armand Immune checkpoint blockade in hematologic malignancies Blood 125 2015 3393 3400
5. D.H. Barouch, K.L. O'Brien, N.L. Simmons, S.L. King, P. Abbink, L.F. Maxfield, Y.H. Sun, A. La Porte, A.M. Riggs, D.M. Lynch, and et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys Nat. Med. 16 2010 319 323
6. D.H. Barouch, K.E. Stephenson, E.N. Borducchi, K. Smith, K. Stanley, A.G. McNally, J. Liu, P. Abbink, L.F. Maxfield, M.S. Seaman, and et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys Cell 155 2013 531 539
7. D.H. Barouch, G. Alter, T. Broge, C. Linde, M.E. Ackerman, E.P. Brown, E.N. Borducchi, K.M. Smith, J.P. Nkolola, J. Liu, and et al. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys Science 349 2015 320 324
8. J.N. Bhiman, C. Anthony, N.A. Doria-Rose, O. Karimanzira, C.A. Schramm, T. Khoza, D. Kitchin, G. Botha, J. Gorman, N.J. Garrett, and et al. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies Nat. Med. 21 2015 1332 1336
9. P. Borrow, H. Lewicki, X. Wei, M.S. Horwitz, N. Peffer, H. Meyers, J.A. Nelson, J.E. Gairin, B.H. Hahn, M.B. Oldstone, and G.M. Shaw Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus Nat. Med. 3 1997 205 211
10. N. Borthwick, T. Ahmed, B. Ondondo, P. Hayes, A. Rose, U. Ebrahimsa, E.J. Hayton, A. Black, A. Bridgeman, M. Rosario, and et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1 Mol. Ther. 22 2014 464 475
11. D.R. Burton, and J.R. Mascola Antibody responses to envelope glycoproteins in HIV-1 infection Nat. Immunol. 16 2015 571 576
12. S.L. Campion, T.M. Brodie, W. Fischer, B.T. Korber, A. Rossetti, N. Goonetilleke, A.J. McMichael, and F. Sallusto Proteome-wide analysis of HIV-specific naive and memory CD4(+) T cells in unexposed blood donors J. Exp. Med. 211 2014 1273 1280
13. J.M. Carlson, M. Schaefer, D.C. Monaco, R. Batorsky, D.T. Claiborne, J. Prince, M.J. Deymier, Z.S. Ende, N.R. Klatt, C.E. DeZiel, and et al. HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck Science 345 2014 1254031
14. D.R. Casimiro, F. Wang, W.A. Schleif, X. Liang, Z.Q. Zhang, T.W. Tobery, M.E. Davies, A.B. McDermott, D.H. O'Connor, A. Fridman, and et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag J. Virol. 79 2005 15547 15555
15. M. Caskey, F. Klein, J.C. Lorenzi, M.S. Seaman, A.P. West Jr., N. Buckley, G. Kremer, L. Nogueira, M. Braunschweig, J.F. Scheid, and et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 Nature 522 2015 487 491
16. Y. Chen, J. Zhang, K.K. Hwang, H. Bouton-Verville, S.M. Xia, A. Newman, Y.B. Ouyang, B.F. Haynes, and L. Verkoczy Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10 J. Immunol. 191 2013 1260 1275
17. J. Chen, G. Frey, H. Peng, S. Rits-Volloch, J. Garrity, M.S. Seaman, and B. Chen Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41 J. Virol. 88 2014 1249 1258
18. E.T. Crooks, T. Tong, B. Chakrabarti, K. Narayan, I.S. Georgiev, S. Menis, X. Huang, D. Kulp, K. Osawa, J. Muranaka, and et al. Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site PLoS Pathog. 11 2015 e1004932
19. S. Crotty T follicular helper cell differentiation, function, and roles in disease Immunity 41 2014 529 542
20. K. Deng, M. Pertea, A. Rongvaux, L. Wang, C.M. Durand, G. Ghiaur, J. Lai, H.L. McHugh, H. Hao, H. Zhang, and et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations Nature 517 2015 381 385
21. C.A. Derdeyn, J.M. Decker, F. Bibollet-Ruche, J.L. Mokili, M. Muldoon, S.A. Denham, M.L. Heil, F. Kasolo, R. Musonda, B.H. Hahn, and et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission Science 303 2004 2019 2022
22. N.A. Doria-Rose, C.A. Schramm, J. Gorman, P.L. Moore, J.N. Bhiman, B.J. DeKosky, M.J. Ernandes, I.S. Georgiev, H.J. Kim, M. Pancera, et al. NISC Comparative Sequencing Program Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies Nature 509 2014 55 62
23. P. Dosenovic, L. von Boehmer, A. Escolano, J. Jardine, N.T. Freund, A.D. Gitlin, A.T. McGuire, D.W. Kulp, T. Oliveira, L. Scharf, and et al. Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice Cell 161 2015 1505 1515
24. T. Doyle, C. Goujon, and M.H. Malim HIV-1 and interferons: who's interfering with whom? Nat. Rev. Microbiol. 13 2015 403 413
25. C. Doyle-Cooper, K.E. Hudson, A.B. Cooper, T. Ota, P. Skog, P.E. Dawson, M.B. Zwick, W.R. Schief, D.R. Burton, and D. Nemazee Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10 J. Immunol. 191 2013 3186 3191
26. A.E. Fenton-May, O. Dibben, T. Emmerich, H. Ding, K. Pfafferott, M.M. Aasa-Chapman, P. Pellegrino, I. Williams, M.S. Cohen, F. Gao, and et al. Relative resistance of HIV-1 founder viruses to control by interferon-alpha Retrovirology 10 2013 146
27. A. Fernández-Tejada, B.F. Haynes, and S.J. Danishefsky Designing synthetic vaccines for HIV Expert Rev. Vaccines 14 2015 815 831
28. G. Ferrari, B. Korber, N. Goonetilleke, M.K. Liu, E.L. Turnbull, J.F. Salazar-Gonzalez, N. Hawkins, S. Self, S. Watson, M.R. Betts, and et al. Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection PLoS Pathog. 7 2011 e1001273
29. W. Fischer, S. Perkins, J. Theiler, T. Bhattacharya, K. Yusim, R. Funkhouser, C. Kuiken, B. Haynes, N.L. Letvin, B.D. Walker, and et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants Nat. Med. 13 2007 100 106
30. C. Fraser, K. Lythgoe, G.E. Leventhal, G. Shirreff, T.D. Hollingsworth, S. Alizon, and S. Bonhoeffer Virulence and pathogenesis of HIV-1 infection: an evolutionary perspective Science 343 2014 1243727
31. F. Gao, M. Bonsignori, H.X. Liao, A. Kumar, S.M. Xia, X. Lu, F. Cai, K.K. Hwang, H. Song, T. Zhou, and et al. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies Cell 158 2014 481 491
32. P.A. Goepfert, M.L. Elizaga, K. Seaton, G.D. Tomaras, D.C. Montefiori, A. Sato, J. Hural, S.C. DeRosa, S.A. Kalams, M.J. McElrath, et al. HVTN 205 Study Group National Institutes of Allergy and Infectious Diseases HIV Vaccines Trials Network Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles J. Infect. Dis. 210 2014 99 110
33. N. Goonetilleke, M.K. Liu, J.F. Salazar-Gonzalez, G. Ferrari, E. Giorgi, V.V. Ganusov, B.F. Keele, G.H. Learn, E.L. Turnbull, M.G. Salazar, et al. CHAVI Clinical Core B The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection J. Exp. Med. 206 2009 1253 1272
34. J. Gorman, C. Soto, M.M. Yang, T.M. Davenport, M. Guttman, R.T. Bailer, M. Chambers, G.Y. Chuang, B.J. DeKosky, N.A. Doria-Rose, and et al. Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design Nat. Struct. Mol. Biol. 23 2015 81 90
35. G.J. Gorse, L.R. Baden, M. Wecker, M.J. Newman, G. Ferrari, K.J. Weinhold, B.D. Livingston, T.L. Villafana, H. Li, E. Noonan, N.D. Russell HIV Vaccine Trials Network Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults Vaccine 26 2008 215 223
36. P.J. Goulder, and B.D. Walker HIV and HLA class I: an evolving relationship Immunity 37 2012 426 440
37. G. Gray, S. Buchbinder, and A. Duerr Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine Curr. Opin. HIV AIDS 5 2010 357 361
38. S. Han, B. Zheng, J. Dal Porto, and G. Kelsoe In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. IV. Affinity-dependent, antigen-driven B cell apoptosis in germinal centers as a mechanism for maintaining self-tolerance J. Exp. Med. 182 1995 1635 1644
39. S.G. Hansen, J.C. Ford, M.S. Lewis, A.B. Ventura, C.M. Hughes, L. Coyne-Johnson, N. Whizin, K. Oswald, R. Shoemaker, T. Swanson, and et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine Nature 473 2011 523 527
40. S.G. Hansen, M. Piatak Jr., A.B. Ventura, C.M. Hughes, R.M. Gilbride, J.C. Ford, K. Oswald, R. Shoemaker, Y. Li, M.S. Lewis, and et al. Immune clearance of highly pathogenic SIV infection Nature 502 2013 100 104
41. S.G. Hansen, J.B. Sacha, C.M. Hughes, J.C. Ford, B.J. Burwitz, I. Scholz, R.M. Gilbride, M.S. Lewis, A.N. Gilliam, A.B. Ventura, and et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms Science 340 2013 1237874
42. S.G. Hansen, H.L. Wu, B.J. Burwitz, C.M. Hughes, K.B. Hammond, A.B. Ventura, J.S. Reed, R.M. Gilbride, E. Ainslie, D.W. Morrow, and et al. Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E Science 2016 aac9475 10.1126/science.aac9475
43. B.F. Haynes, and L. Verkoczy AIDS/HIV. Host controls of HIV neutralizing antibodies Science 344 2014 588 589
44. B.F. Haynes, J. Fleming, E.W. St Clair, H. Katinger, G. Stiegler, R. Kunert, J. Robinson, R.M. Scearce, K. Plonk, H.F. Staats, and et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies Science 308 2005 1906 1908
45. B.F. Haynes, P.B. Gilbert, M.J. McElrath, S. Zolla-Pazner, G.D. Tomaras, S.M. Alam, D.T. Evans, D.C. Montefiori, C. Karnasuta, R. Sutthent, and et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial N. Engl. J. Med. 366 2012 1275 1286
46. B.F. Haynes, G. Kelsoe, S.C. Harrison, and T.B. Kepler B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study Nat. Biotechnol. 30 2012 423 433
47. P. Hraber, M.S. Seaman, R.T. Bailer, J.R. Mascola, D.C. Montefiori, and B.T. Korber Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection AIDS 28 2014 163 169
48. J. Huang, G. Ofek, L. Laub, M.K. Louder, N.A. Doria-Rose, N.S. Longo, H. Imamichi, R.T. Bailer, B. Chakrabarti, S.K. Sharma, and et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody Nature 491 2012 406 412
49. Y. Huang, D. Follmann, M. Nason, L. Zhang, Y. Huang, D.V. Mehrotra, Z. Moodie, B. Metch, H. Janes, M.C. Keefer, and et al. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials PLoS ONE 10 2015 e0136626
50. S.L. Hulot, B. Korber, E.E. Giorgi, N. Vandergrift, K.O. Saunders, H. Balachandran, L.V. Mach, M.A. Lifton, G. Pantaleo, J. Tartaglia, and et al. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost J. Virol. 89 2015 6462 6480
51. D.J. Irvine, M.A. Purbhoo, M. Krogsgaard, and M.M. Davis Direct observation of ligand recognition by T cells Nature 419 2002 845 849
52. W. Jaoko, F.N. Nakwagala, O. Anzala, G.O. Manyonyi, J. Birungi, A. Nanvubya, F. Bashir, K. Bhatt, H. Ogutu, S. Wakasiaka, and et al. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa Vaccine 26 2008 2788 2795
53. J.G. Jardine, T. Ota, D. Sok, M. Pauthner, D.W. Kulp, O. Kalyuzhniy, P.D. Skog, T.C. Thinnes, D. Bhullar, B. Briney, and et al. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen Science 349 2015 156 161
54. N.A. Jones, X. Wei, D.R. Flower, M. Wong, F. Michor, M.S. Saag, B.H. Hahn, M.A. Nowak, G.M. Shaw, and P. Borrow Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response J. Exp. Med. 200 2004 1243 1256
55. S.A. Joosten, K.E. van Meijgaarden, P.C. van Weeren, F. Kazi, A. Geluk, N.D. Savage, J.W. Drijfhout, D.R. Flower, W.A. Hanekom, M.R. Klein, and T.H. Ottenhoff Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity PLoS Pathog. 6 2010 e1000782
56. S.B. Joseph, R. Swanstrom, A.D. Kashuba, and M.S. Cohen Bottlenecks in HIV-1 transmission: insights from the study of founder viruses Nat. Rev. Microbiol. 13 2015 414 425
57. J.P. Julien, A. Cupo, D. Sok, R.L. Stanfield, D. Lyumkis, M.C. Deller, P.J. Klasse, D.R. Burton, R.W. Sanders, J.P. Moore, and et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer Science 342 2013 1477 1483
58. S.A. Kalams, S.D. Parker, M. Elizaga, B. Metch, S. Edupuganti, J. Hural, S. De Rosa, D.K. Carter, K. Rybczyk, I. Frank, et al. NIAID HIV Vaccine Trials Network Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery J. Infect. Dis. 208 2013 818 829
59. B.F. Keele, E.E. Giorgi, J.F. Salazar-Gonzalez, J.M. Decker, K.T. Pham, M.G. Salazar, C. Sun, T. Grayson, S. Wang, H. Li, and et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection Proc. Natl. Acad. Sci. USA 105 2008 7552 7557
60. P. Kiepiela, K. Ngumbela, C. Thobakgale, D. Ramduth, I. Honeyborne, E. Moodley, S. Reddy, C. de Pierres, Z. Mncube, N. Mkhwanazi, and et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load Nat. Med. 13 2007 46 53
61. M. Kim, L. Song, J. Moon, Z.Y. Sun, A. Bershteyn, M. Hanson, D. Cain, S. Goka, G. Kelsoe, G. Wagner, and et al. Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry J. Biol. Chem. 288 2013 31888 31901
62. F. Klein, H. Mouquet, P. Dosenovic, J.F. Scheid, L. Scharf, and M.C. Nussenzweig Antibodies in HIV-1 vaccine development and therapy Science 341 2013 1199 1204
63. J.E. Ledgerwood, E.E. Coates, G. Yamshchikov, J.G. Saunders, L. Holman, M.E. Enama, A. DeZure, R.M. Lynch, I. Gordon, S. Plummer, et al. VRC 602 Study Team Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults Clin. Exp. Immunol. 182 2015 289 301
64. S. Létourneau, E.J. Im, T. Mashishi, C. Brereton, A. Bridgeman, H. Yang, L. Dorrell, T. Dong, B. Korber, A.J. McMichael, and T. Hanke Design and pre-clinical evaluation of a universal HIV-1 vaccine PLoS ONE 2 2007 e984
65. D.M. Lewinsohn, M.R. Alderson, A.L. Briden, S.R. Riddell, S.G. Reed, and K.H. Grabstein Characterization of human CD8+ T cells reactive with Mycobacterium tuberculosis-infected antigen-presenting cells J. Exp. Med. 187 1998 1633 1640
66. Q. Li, J.D. Estes, P.M. Schlievert, L. Duan, A.J. Brosnahan, P.J. Southern, C.S. Reilly, M.L. Peterson, N. Schultz-Darken, K.G. Brunner, and et al. Glycerol monolaurate prevents mucosal SIV transmission Nature 458 2009 1034 1038
67. H.X. Liao, X. Chen, S. Munshaw, R. Zhang, D.J. Marshall, N. Vandergrift, J.F. Whitesides, X. Lu, J.S. Yu, K.K. Hwang, and et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated J. Exp. Med. 208 2011 2237 2249
68. H.X. Liao, R. Lynch, T. Zhou, F. Gao, S.M. Alam, S.D. Boyd, A.Z. Fire, K.M. Roskin, C.A. Schramm, Z. Zhang, and et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus Nature 496 2013 469 476
69. J. Liu, K.L. O'Brien, D.M. Lynch, N.L. Simmons, A. La Porte, A.M. Riggs, P. Abbink, R.T. Coffey, L.E. Grandpre, M.S. Seaman, and et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys Nature 457 2009 87 91
70. M.K. Liu, N. Hawkins, A.J. Ritchie, V.V. Ganusov, V. Whale, S. Brackenridge, H. Li, J.W. Pavlicek, F. Cai, M. Rose-Abrahams, et al. CHAVI Core B Vertical T cell immunodominance and epitope entropy determine HIV-1 escape J. Clin. Invest. 123 2013 380 393
71. M. Liu, G. Yang, K. Wiehe, N.I. Nicely, N.A. Vandergrift, W. Rountree, M. Bonsignori, S.M. Alam, J. Gao, B.F. Haynes, and G. Kelsoe Polyreactivity and autoreactivity among HIV-1 antibodies J. Virol. 89 2015 784 798
72. M. Locci, C. Havenar-Daughton, E. Landais, J. Wu, M.A. Kroenke, C.L. Arlehamn, L.F. Su, R. Cubas, M.M. Davis, A. Sette, et al. International AIDS Vaccine Initiative Protocol C Principal Investigators Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses Immunity 39 2013 758 769
73. D. Lyumkis, J.P. Julien, N. de Val, A. Cupo, C.S. Potter, P.J. Klasse, D.R. Burton, R.W. Sanders, J.P. Moore, B. Carragher, and et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer Science 342 2013 1484 1490
74. J.R. Mascola, and B.F. Haynes HIV-1 neutralizing antibodies: understanding nature's pathways Immunol. Rev. 254 2013 225 244
75. M.J. McElrath, S.C. De Rosa, Z. Moodie, S. Dubey, L. Kierstead, H. Janes, O.D. Defawe, D.K. Carter, J. Hural, R. Akondy, et al. Step Study Protocol Team HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis Lancet 372 2008 1894 1905
76. S.A. Migueles, and M. Connors Success and failure of the cellular immune response against HIV-1 Nat. Immunol. 16 2015 563 570
77. B. Moldt, E.G. Rakasz, N. Schultz, P.Y. Chan-Hui, K. Swiderek, K.L. Weisgrau, S.M. Piaskowski, Z. Bergman, D.I. Watkins, P. Poignard, and D.R. Burton Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo Proc. Natl. Acad. Sci. USA 109 2012 18921 18925
78. M.A. Moody, F. Gao, T.C. Gurley, J.D. Amos, A. Kumar, B. Hora, D.J. Marshall, J.F. Whitesides, S.M. Xia, R. Parks, and et al. Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses Cell Host Microbe 18 2015 354 362
79. P.L. Moore, E.S. Gray, C.K. Wibmer, J.N. Bhiman, M. Nonyane, D.J. Sheward, T. Hermanus, S. Bajimaya, N.L. Tumba, M.R. Abrahams, and et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape Nat. Med. 18 2012 1688 1692
80. B. Mothe, A. Llano, J. Ibarrondo, M. Daniels, C. Miranda, J. Zamarreño, V. Bach, R. Zuniga, S. Pérez-Álvarez, C.T. Berger, and et al. Definition of the viral targets of protective HIV-1-specific T cell responses J. Transl. Med. 9 2011 208
81. B. Mothe, X. Hu, A. Llano, M. Rosati, A. Olvera, V. Kulkarni, A. Valentin, C. Alicea, G.R. Pilkington, N.Y. Sardesai, and et al. A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques J. Transl. Med. 13 2015 60
82. H. Mouquet, J.F. Scheid, M.J. Zoller, M. Krogsgaard, R.G. Ott, S. Shukair, M.N. Artyomov, J. Pietzsch, M. Connors, F. Pereyra, and et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation Nature 467 2010 591 595
83. K.L. Mueller Cancer immunology and immunotherapy. Realizing the promise. Introduction Science 348 2015 54 55
84. G. Ofek, F.J. Guenaga, W.R. Schief, J. Skinner, D. Baker, R. Wyatt, and P.D. Kwong Elicitation of structure-specific antibodies by epitope scaffolds Proc. Natl. Acad. Sci. USA 107 2010 17880 17887
85. M. Pancera, T. Zhou, A. Druz, I.S. Georgiev, C. Soto, J. Gorman, J. Huang, P. Acharya, G.Y. Chuang, G. Ofek, and et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env Nature 514 2014 455 461
86. N.F. Parrish, F. Gao, H. Li, E.E. Giorgi, H.J. Barbian, E.H. Parrish, L. Zajic, S.S. Iyer, J.M. Decker, A. Kumar, and et al. Phenotypic properties of transmitted founder HIV-1 Proc. Natl. Acad. Sci. USA 110 2013 6626 6633
87. L.H. Ping, S.B. Joseph, J.A. Anderson, M.R. Abrahams, J.F. Salazar-Gonzalez, L.P. Kincer, F.K. Treurnicht, L. Arney, S. Ojeda, M. Zhang, et al. CAPRISA Acute Infection Study and the Center for HIV-AIDS Vaccine Immunology Consortium Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design J. Virol. 87 2013 7218 7233
88. S.A. Plotkin Correlates of protection induced by vaccination Clin. Vaccine Immunol. 17 2010 1055 1065
89. B. Pulendran, G. Kannourakis, S. Nouri, K.G. Smith, and G.J. Nossal Soluble antigen can cause enhanced apoptosis of germinal-centre B cells Nature 375 1995 331 334
90. O.G. Pybus, and A. Rambaut Evolutionary analysis of the dynamics of viral infectious disease Nat. Rev. Genet. 10 2009 540 550
91. S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, et al. MOPH-TAVEG Investigators Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand N. Engl. J. Med. 361 2009 2209 2220
92. M. Roederer, B.F. Keele, S.D. Schmidt, R.D. Mason, H.C. Welles, W. Fischer, C. Labranche, K.E. Foulds, M.K. Louder, Z.Y. Yang, and et al. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV Nature 505 2014 502 508
93. M. Rolland, D.C. Nickle, and J.I. Mullins HIV-1 group M conserved elements vaccine PLoS Pathog. 3 2007 e157
94. J.B. Sacha, C. Chung, E.G. Rakasz, S.P. Spencer, A.K. Jonas, A.T. Bean, W. Lee, B.J. Burwitz, J.J. Stephany, J.T. Loffredo, and et al. Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression J. Immunol. 178 2007 2746 2754
95. R.W. Sanders, M.J. van Gils, R. Derking, D. Sok, T.J. Ketas, J.A. Burger, G. Ozorowski, A. Cupo, C. Simonich, L. Goo, and et al. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers Science 349 2015 aac4223
96. N.G. Sandler, S.E. Bosinger, J.D. Estes, R.T. Zhu, G.K. Tharp, E. Boritz, D. Levin, S. Wijeyesinghe, K.N. Makamdop, G.Q. del Prete, and et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression Nature 511 2014 601 605
97. S. Santra, H.X. Liao, R. Zhang, M. Muldoon, S. Watson, W. Fischer, J. Theiler, J. Szinger, H. Balachandran, A. Buzby, and et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys Nat. Med. 16 2010 324 328
98. C.N. Scanlan, G.E. Ritchie, K. Baruah, M. Crispin, D.J. Harvey, B.B. Singer, L. Lucka, M.R. Wormald, P. Wentworth Jr., N. Zitzmann, and et al. Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralising, HIV-1 specific antibody J. Mol. Biol. 372 2007 16 22
99. G.M. Shaw, and E. Hunter HIV transmission Cold Spring Harb. Perspect. Med. 2 2012 10.1101/cshperspect.a006965
100. J.W. Shiver, T.M. Fu, L. Chen, D.R. Casimiro, M.E. Davies, R.K. Evans, Z.Q. Zhang, A.J. Simon, W.L. Trigona, S.A. Dubey, and et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity Nature 415 2002 331 335
101. K.M. Shokat, and C.C. Goodnow Antigen-induced B-cell death and elimination during germinal-centre immune responses Nature 375 1995 334 338
102. H. Stein, J. Gerdes, and D.Y. Mason The normal and malignant germinal centre Clin. Haematol. 11 1982 531 559
103. L.F. Su, B.A. Kidd, A. Han, J.J. Kotzin, and M.M. Davis Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults Immunity 38 2013 373 383
104. G.D. Tomaras, N.L. Yates, P. Liu, L. Qin, G.G. Fouda, L.L. Chavez, A.C. Decamp, R.J. Parks, V.C. Ashley, J.T. Lucas, and et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia J. Virol. 82 2008 12449 12463
105. A.M. Trama, M.A. Moody, S.M. Alam, F.H. Jaeger, B. Lockwood, R. Parks, K.E. Lloyd, C. Stolarchuk, R. Scearce, A. Foulger, and et al. HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria Cell Host Microbe 16 2014 215 226
106. A. Velardi, M.C. Mingari, L. Moretta, and C.E. Grossi Functional analysis of cloned germinal center CD4+ cells with natural killer cell-related features. Divergence from typical T helper cells J. Immunol. 137 1986 2808 2813
107. L. Verkoczy, M. Diaz, T.M. Holl, Y.B. Ouyang, H. Bouton-Verville, S.M. Alam, H.X. Liao, G. Kelsoe, and B.F. Haynes Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance Proc. Natl. Acad. Sci. USA 107 2010 181 186
108. L. Verkoczy, Y. Chen, H. Bouton-Verville, J. Zhang, M. Diaz, J. Hutchinson, Y.B. Ouyang, S.M. Alam, T.M. Holl, K.K. Hwang, and et al. Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controls J. Immunol. 187 2011 3785 3797
109. L. Verkoczy, Y. Chen, J. Zhang, H. Bouton-Verville, A. Newman, B. Lockwood, R.M. Scearce, D.C. Montefiori, S.M. Dennison, S.M. Xia, and et al. Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses J. Immunol. 191 2013 2538 2550
110. A.P. West Jr., L. Scharf, J.F. Scheid, F. Klein, P.J. Bjorkman, and M.C. Nussenzweig Structural insights on the role of antibodies in HIV-1 vaccine and therapy Cell 156 2014 633 648
111. W.B. Williams, H.X. Liao, M.A. Moody, T.B. Kepler, S.M. Alam, F. Gao, K. Wiehe, A.M. Trama, K. Jones, R. Zhang, and et al. HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies Science 349 2015 aab1253
112. G. Yang, T.M. Holl, Y. Liu, Y. Li, X. Lu, N.I. Nicely, T.B. Kepler, S.M. Alam, H.X. Liao, D.W. Cain, and et al. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies J. Exp. Med. 210 2013 241 256
113. D. Yu, and C.G. Vinuesa Multiple checkpoints keep follicular helper T cells under control to prevent autoimmunity Cell. Mol. Immunol. 7 2010 198 203
114. L. Yue, K.J. Pfafferott, J. Baalwa, K. Conrod, C.C. Dong, C. Chui, R. Rong, D.T. Claiborne, J.L. Prince, J. Tang, and et al. Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients PLoS Pathog. 11 2015 e1004565
115. T. Zhou, R.M. Lynch, L. Chen, P. Acharya, X. Wu, N.A. Doria-Rose, M.G. Joyce, D. Lingwood, C. Soto, R.T. Bailer, et al. NISC Comparative Sequencing Program Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors Cell 161 2015 1280 1292